我们为患者和疾病的抗争，开辟一条
更有希望的前进道路
我们只有一个目标：
将开创性的科学研究成果转化为对抗难以治疗的癌症和神经退行性疾病的新希望。临床试验是这一转化过程中的关键一步，它为患者提供了在广泛应用之前接触创新研究性疗法的机会。
我们邀请医生和患者探索下面列出的临床研究。每一项试验都代表着一条新的前进道路，也是迈向治愈的一步。
如果您或您关心的人正在与癌症作斗争，欢迎您了解更多信息并与我们联系。
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Indications: advanced or metastatic non-small cell lung cancers, colorectal cancers and angiosarcoma.
A Phase 3 study of gotistobart versus docetaxel
Indications: Squamous cell carcinoma of the lung that progressed on chemotherapy and PD-1/PD-L1 inhibitor immunotherapy.
我们衷心感谢每一位参与这些重要试验的患者、护理人员及家属。我们的承诺永续，并期待未来能与医学界分享这些宝贵的研究
成果。
A Phase 1 open-label study of gotistobart as a monotherapy and in combination with Pembrolizumab
Indications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab
Indications: Platinum-resistant ovarian cancer
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan
Indications: Metastatic Castration-resistant Prostate Cancer
